

Supplementary Table 1. Baseline Characteristics of Lupus Nephritis ESRD patients 1995-2008 in the U.S., who were Medicare A+B recipients (included in analyses of non-fatal CV events)

	Total N= 6,064	Whites N= 2,566	African Americ ns N= 3,180	Asians N= 255	Native- Americans N= 63	p value*	Non- Hispanics N= 5,141	Hispanics N=923	p value*
Demographics									
Female	4,912 (81.0%)	1,958 (76.3%)	2,695 (84.7%)	208 (81.5%)	51 (80.9%)	<0.0001	4,174 (81.1%)	738 (79.9%)	0.37
Mean age at ESRD onset	41.82 ± 16.50	45.89 ± 18.34	39.04 ± 14.31	36.41 ± 13.93	38.27 ± 14.19	<0.0001	42.78 ± 16.70	36.44 ± 14.20	<0.0001
Laboratory measures									
Hemoglobin (g/dl)	9.31 ± 1.81	9.61 ± 1.81	9.06 ± 1.76	9.44 ± 2.01	9.44 ± 2.07	<0.0001	9.31 ± 1.81	9.30 ± 1.85	0.83
eGFR (ml/min/1.73m ²) (N=6,025)	8.03 ± 4.67	8.64 ± 4.71	7.50 ± 4.60	8.32 ± 4.57	8.40 ± 3.94	<0.0001	8.01 ± 4.69	8.15± 4.59	0.41
Serum albumin (g/dl) (N=4,929)	2.88± 0.78	3.00 ± 0.76	2.79± 0.79	2.81 ± 0.79	2.66 ± 0.81	<0.0001	2.87 ± 0.78	2.90 ± 0.81	0.34
Mean BMI (kg/m ²) (N=5,816)	26.24 ± 7.21	25.77 ± 6.85	26.83 ± 7.55	23.68 ± 5.74	25.59 ± 6.04	<0.0001	26.25 ± 7.29	26.19 ± 6.77	0.82
Erythropoietin Stimulating Agent use									
	1,992 (32.8%)	931 (36.2%)	948 (29.8%)	93 (36.4%)	20 (31.7%)	<0.0001	1,701 (33.0%)	291 (31.5%)	0.35
Comorbidities									
Hypertension	4,739 (78.2%)	1,937 (75.5%)	2,561 (80.5%)	189 (74.1%)	52 (82.5%)	<0.0001	4,045 (78.6%)	694 (75.1%)	0.01
Current Smoking	291 (4.8%)	161 (6.2%)	120 (3.7%)	-	-	<0.0001	270 (5.2%)	21 (2.2%)	<0.0001
Diabetes Mellitus	589 (9.1%)	249 (9.7%)	322 (10.1%)	-	-	0.07	504 (9.8%)	85 (9.2%)	0.57
Heart Failure	1,086 (17.9%)	511 (19.9%)	529 (16.6%)	31 (12.1%)	15 (23.8%)	0.0005	956 (18.6%)	130 (14.0%)	0.001
Coronary Artery Disease	465 (7.6%)	297 (11.5%)	158 (4.9%)	-	-	<0.0001	421 (8.1%)	44 (4.7%)	0.0003

Cerebrovascular Accident	370 (6.1%)	187 (7.3%)	166 (5.2%)	-	-	0.008	323 (6.3%)	47 (5.1%)	0.16
Peripheral Vascular Disease	244 (4.0%)	128 (5.0%)	106 (3.3%)	-	-	0.001	217 (4.2%)	27 (2.9%)	0.06
Chronic Obstructive Pulmonary Disease	189 (3.1%)	120 (4.7%)	65 (2.0%)	-	-	<0.0001	177 (3.4%)	12 (1.3%)	0.0006
Cancer	97 (1.6%)	59 (2.3%)	35 (1.1%)	-	-	0.002	92 (1.8%)	-	0.005
Medical Insurance									
No Insurance	874 (14.4%)	330 (12.8%)	505 (15.8%)	35 (13.7%)	-	0.002	691 (13.4%)	183 (19.8%)	<0.0001
Medicare	1,397 (23%)	823 (32.0%)	531 (16.7%)	33 (12.9%)	-	<0.0001	1,301 (25.3%)	96 (10.4%)	<0.0001
Medicaid	2,637 (43.4%)	906 (35.3%)	1599 (50.2%)	93 (36.4%)	39 (61.9%)	<0.0001	2,193 (42.6%)	444 (48.1%)	0.002
Private	627 (10.3%)	261 (10.1%)	322 (10.1%)	39 (15.3%)	-	0.06	534 (10.4%)	93 (10.0%)	0.77
Other	490 (8.0%)	229 (8.9%)	202 (6.3%)	54 (21.1%)	-	<0.0001	396 (7.7%)	94 (10.1%)	0.0008
Region of Residence									
Northeast	891 (14.7%)	422 (16.4%)	433 (13.6%)	34 (13.3%)	-	0.001	772 (15.0%)	119 (12.9%)	0.09
West	977 (16.1%)	602 (23.4%)	213 (6.7%)	141 (55.3%)	21 (33.3%)	<0.0001	672 (13.0%)	305 (33.0%)	<0.0001
South	3,010 (49.6%)	969 (37.7%)	1,975 (62.1%)	44 (17.2%)	22 (34.9%)	<0.0001	2,652 (51.6%)	358 (38.8%)	<0.0001
Midwest	1,101 (18.1%)	509 (18.8%)	549 (17.2%)	25 (9.8%)	18 (28.5%)	<0.0001	1,028 (20.0%)	73 (7.9%)	<0.0001
Other territories	85 (1.4%)	64 (2.5%)	-	-	-	<0.0001	17 (0.3%)	68 (7.3%)	<0.0001
Area-Level Socioeconomic Status (SES)									
Lowest Quartile of SES in USRDS	29.2%	29.3%	30.5%	6.2%	52.3%	<0.0001	31.4%	16.0%	<0.0001
Initial ESRD Modality ¥									
Hemodialysis	5,098	2,042	2,790	213	53	<0.0001	4,327	771	0.62

	(84.0%)	(79.5%)	(87.7%)	(83.5%)	(79.6%)		(84.15)	(83.5%)	
Peritoneal dialysis	611 (10.0%)	303 (11.8%)	272 (8.5%)	28 (10.9%)	-	0.0006	500 (9.7%)	111 (12.0%)	0.03
Pre-emptive transplant	79 (1.3%)	64 (2.5%)	12 (0.38%)	-	-	<0.0001	67 (1.3%)	12 (1.3%)	0.99

Cell sizes < 11 suppressed per Federal research regulations.

*Chi-squared tests for categorical values and t- tests for continuous variables. With Bonferroni correction for multiple comparisons, threshold for statistical significance= 0.025

¥ 4.55% of patients were classified as uncertain for the initial renal replacement modality in the Medical Evidence Report at entry into USRDS.

Supplementary Table 2. Unadjusted Incidence Rates for Hospital Non-fatal Admissions for Cardiovascular Events among Patients with Lupus Nephritis ESRD in the U.S., 1995-2008

	Heart Failure			Myocardial Infarction			Ischemic Stroke			Hemorrhagic Stroke		
	Number of Events	Person years	IR* (95% CI)	Number of Events	Person years	IR* (95% CI)	Number of Events	Person years	IR* (95% CI)	Number of Events	Person years	IR* (95% CI)
All patients	3,477	39,898	87.1 (84.3-90.1)	724	47,657	15.1 (14.1-16.3)	691	47,515	14.5 (13.5-15.6)	253	48,482	5.2 (4.6-5.9)
Race												
White	1,378	17,752	77.6 (73.6-81.8)	343	20,412	16.8 (15.1-18.6)	308	20,411	15.0 (13.5-16.8)	86	20,829	4.1 (3.3-5.1)
African American	1,955	19,370	100.9 (96.5-105.5)	352	24,163	14.5 (13.1-16.1)	363	24,004	15.1 (13.6-16.7)	150	24,531	6.1 (5.2-7.1)
Asian	105	2,444	42.9 (35.4-52.0)	25	2,657	9.4 (6.3-13.9)	17	2,671	6.3 (3.9-10.2)	13	2,694	4.8 (2.8-8.3)
Native American	39	330	117.9 (86.1-161.4)	--	424	9.4 (3.5-25.1)	--	427	7.0 (2.2-21.7)	--	427	9.3 (3.5-24.9)

Ethnicity												
Non-Hispanic	3,060	32,914	92.9 (89.7-96.3)	647	39,589	16.3 (15.1-17.6)	615	39,465	15.5 (14.4-16.8)	226	40,324	5.6 (4.9-6.3)
Hispanic	417	6,983	59.7 (54.2-65.7)	77	8,067	9.5 (7.6-11.9)	76	8,049	9.4 (7.5-11.9)	27	8,158	3.3 (2.2-4.8)

* IR= Incidence rate per 1,000 SLE patients in USRDS per year. Cell sizes < 11 suppressed per Federal research regulations